In this retrospective case series that included 69 adults in Wuhan, 29% of patients showed dyspnea and 20% of cases showed SpO2<90%. Patients with SpO2<90% had a significantly higher risk of death. Abidol showed initial therapeutic effect. ABSTRACT Background

ObjectiveT cell receptor (TCR) diversity determines the autoimmune responses in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and is closely associated with autoimmune diseases prognosis and prevention. However, the characteristics of variations in TCR diversity and their clinical significance is still unknown. Large series of patients must be studied in order to elucidate the effects of these variations.MethodsPeripheral blood from 877 SLE patients, 206 RA patients and 439 healthy controls (HC) were amplified for the TCR repertoire and sequenced using a high-throughput sequencer. We have developed a statistical model to identify disease-associated TCR clones and diagnose autoimmune diseases.ResultsSignificant differences were identified in variable (V), joining (J) and V-J pairing between the SLE or RA and HC groups. These differences can be utilised to discriminate the three groups with perfect accuracy (V: area under receiver operating curve > 0.99). One hundred ninety-eight SLE-associated and 53 RA-associated TCRs were identified and used for diseases classification by cross validation with high specificity and sensitivity. Disease-associated clones showed common features and high similarity between both autoimmune diseases. SLE displayed higher TCR heterogeneity than RA with several organ specific properties. Furthermore, the association between clonal expansion and the concentration of disease-associated clones with disease severity were identified, and pathogen-related TCRs were enriched in both diseases.ConclusionsThese characteristics of the TCR repertoire, particularly the disease-associated clones, can potentially serve as biomarkers and provide novel insights for disease status and therapeutical targets in autoimmune diseases.

Nanostructured lipid carriers (NLCs) are modified solid lipid nanoparticles (SLNs) that retain the characteristics of the SLN, improve drug stability and loading capacity, and prevent drug leakage. Polymer nanoparticles (PNPs) are an important component of drug delivery. These nanoparticles can effectively direct drug delivery to specific targets and improve drug stability and controlled drug release. Lipid–polymer nanoparticles (PLNs), a new type of carrier that combines liposomes and polymers, have been employed in recent years. These nanoparticles possess the complementary advantages of PNPs and liposomes. A PLN is composed of a core–shell structure; the polymer core provides a stable structure, and the phospholipid shell offers good biocompatibility. As such, the two components increase the drug encapsulation efficiency rate, facilitate surface modification, and prevent leakage of water-soluble drugs. Hence, we have reviewed the current state of development for the NLCs’, PNPs’, and PLNs’ structures, preparation, and applications over the past five years, to provide the basis for further study on a controlled release drug delivery system.

No abstract

Potential applications of sodium-ion batteries (SIBs) have motivated significant research interest in grid-scale energy storage. However, large radius of Na ions results in different electrochemical behaves. Therefore, synergistic understanding of the differences is greatly interested for future development of SIBs. Surface availability for ions with poor affinity to electrode materials is critical to rate performance in SIBs, but yet has rarely been reported. Here, to overcome the obstacles of material platform, amorphous TiO2 inverse opal is employed as a proof-of-concept prototype to illuminate the effects of surface ion availability and its relationship between solvent wettability and rate capability. Within expectation, superior rate capabilities are 2 achieved in return for enhanced solvent wettability, regardless of the type of electrolyte and the ion concentration in electrolyte. Even when the anode is cycled at a current density as high as 5000 mA g-1 , the reversible capacity could still retain a high value of ~113 mA h g-1. Our concept opens up a promising avenue to realize full potential of designing electrode materials for SIBs by adjusting the surface kinetics. This understanding shall extend the design principle to electrode materials for highly effective energy storage using other transport ions and other storage mechanisms.

No abstract

No abstract

Copper-based bimetallic catalysts have been recently showing promising performance for the selective electrochemical reduction of CO2. In this work, we successfully fabricated the partially reduced oxides SnOx, CuOxmodified Cu foam electrode (A-Cu/SnO2) through an electrodeposition-annealing-electroreduction approach. Notably, in comparison with the control electrode (Cu/SnO2) without undergoing annealing step, A-Cu/SnO2 exhibits a significant enhancement in terms of CO2 reduction activity and CO selectivity. By investigating the effect of the amount of the electrodeposited SnO2, it is found that A-Cu/SnO2 electrodes present the characteristic Sn-Cu synergistic catalysis with a feature of dominant CO formation (CO faradaic efficiency, 70~75%), the least HCOOH formation (HCOOH faradaic efficiency, <5%) and the remarkable inhibition of hydrogen evolution reaction. In contrast, Cu/SnO2 electrodes exhibit a SnO2 coverage-dependent catalysis—a shift from CO selectivity to HCOOH selectivity with the increasing deposited SnO2 on Cu foam. The different catalytic performance between Cu/SnO2 and A-Cu/SnO2 might be attributed to the different content of Cu atoms in SnO2 layer, which may affect the density of Cu-Sn interface on the surface. Our work provides a facile annealing-electroreduction strategy to modify the surface composition for understanding the metal effect towards CO2 reduction activity and selectivity for bimetallic Cu-based electrocatalysts.